NOT-EB-24-021: Notice of NIBIB Participation in RFA-EY-25-001: "BRAIN Initiative: New Concepts and Early-Stage Research for Recording and Modulation in the Nervous System (R21) (Clinical Trial Not Allowed)"

Notice of NIBIB Participation in RFA-EY-25-001: "BRAIN Initiative: New Concepts and Early-Stage Research for Recording and Modulation in the Nervous System (R21) (Clinical Trial Not Allowed)"

Notice Number:

NOT-EB-24-021

Key Dates

Release Date:

December 30, 2024

Related Announcements

December 09, 2024 - BRAIN Initiative: New Concepts and Early-Stage Research for Recording and Modulation in the Nervous System (R21) (Clinical Trial Not Allowed). See NOFO RFA-EY-25-001.

Issued by

National Institute of Biomedical Imaging and Bioengineering (NIBIB)

Purpose

The purpose of this Notice is to inform potential applicants that effective December 31, 2024, the National Institute of Biomedical Imaging and Bioengineering (NIBIB) will participate in RFA-EY-25-001, "BRAIN Initiative: New Concepts and Early-Stage Research for Recording and Modulation in the Nervous System (R21) (Clinical Trial Not Allowed)", issued by the National Institutes of Health.

The following text has been added to reflect NIBIB’s participation in the NOFO:

Part 1. Overview Information

Components of Participating Organizations

National Institute of Biomedical Imaging and Bioengineering (NIBIB)

Catalog of Federal Domestic Assistance (CFDA) Number(s)

93.286

All other aspects of the NOFO remain the same.

Inquiries

Please direct all inquiries to:

Michael Wolfson
NIBIB/OPESP
Telephone: 301-451-4778
Email: [email protected]